The association between the parameters of uroflowmetry and lower urinary tract symptoms in prostate cancer patients after robot-assisted radical prostatectomy

Yuta Takeshima, Yuta Yamada, Kotaro Takemura, Naoki Kimura, Yuji Hakoizaki, Jimpei Miyakawa, Satoru Taguchi, Yoshiyuki Akiyama, Yusuke Sato, Taketo Kawai, Daisuke Yamada, Tetsuya Fujimura, Haruki Kume

1 Division of Innovative Cancer Therapy, Advanced Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 2 Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3 Department of Urology, Jichi Medical University, Tochigi, Japan

These authors contributed equally to this work.
* yyamada2029@gmail.com

Abstract

Objective
To investigate changes in uroflowmetry parameters in men undergoing robot-assisted radical prostatectomy (RARP) for prostate cancer.

Materials and methods
Four hundred and twenty-eight patients received uroflowmetry testing before and after RARP from November 2011 to December 2018. Clinicopathological data, including age, initial prostate-specific antigen (PSA), prostate volume, clinical stage, body mass index (BMI), uroflowmetry parameters, and core lower urinary tract symptom scores (CLSS) were retrospectively obtained from clinical records. Changes in uroflowmetry parameters were analyzed for statistical predictors and effects on post-operative outcomes.

Results
A significant increase in maximum flow rate (MFR) and decreases in voided volume (VV) and post-void residual urine (PVR) were seen. In multivariate analysis, age was a negative predictor of MFR increase, while prostate volume was a positive predictor of PVR decrease and MFR increase. VV decrease led to worse incontinence symptoms, while PVR decrease and MFR increase led to improvement in voiding symptoms such as slow stream and straining. Continence recovery curves showed that VV decrease were associated with a delay in continence recovery.
Conclusions
Significant changes were seen in uroflowmetry results after RARP, each parameter directly related to urinary symptoms. In particular, VV decrease was associated with a worsening of incontinence symptoms and continence recovery.

Introduction
Prostate cancer is the most common malignancy and the second leading cause of cancer death in men in the United States [1]. Robot-assisted radical prostatectomy (RARP) has become the most prevalent treatment modality for localized prostate cancer in the past two decades [2]. Owing to multiple studies conducting pre-and post-RARP urodynamic studies, we have gained knowledge about the influence surgery has on lower urinary tract symptoms (LUTS) and the underlying mechanism [3–7]. However, urodynamic analysis is an invasive and time-consuming test, and it has been pointed out that it should not be conducted routinely in the absence of value in a clinical setting [8]. Uroflowmetry (UFM), on the other hand, is a non-invasive procedure which measures natural micturition parameters and can be easily conducted on a routine basis with minimal burden on the patient. Unfortunately, previous studies of UFM conducted before and after prostatectomy have concentrated on the parameter changes, and very few have established a connection to clinical results such as post-operative incontinence or quality of life (QOL). In this study, we examined these changes in UFM parameters before and after RARP, and further explored their clinical significance, firstly by examining the pre-operative factors that affected these changes, and secondly by examining how these changes in turn affected clinical outcomes such as incontinence recovery and questionnaire results.

Materials and methods
Patient population
A total of 630 patients underwent RARP at the University of Tokyo Hospital from November 2011 to December 2018. RARP was performed by multiple experienced surgeons using da Vinci®Si or Xi Surgical Systems (Intuitive Surgical, Sunnyvale, CA, USA) by a transperitoneal approach as described in our previous studies [9]. Patients with non-metastatic prostate cancer with or without neoadjuvant hormonal therapy were treated with RARP. Of these patients, UFM was conducted immediately before and 3 to 6 months after RARP in 444 cases. Three patients who developed post-operative anastomotic/ural stricture and received treatment were excluded due to effects on micturition parameters from treatment of stricture. Thirteen patients who received neoadjuvant hormone therapy were excluded due to possible effects on baseline parameters. Overall, a total of 428 patients were eligible for the final analysis (Fig 1). In addition to the UFM data, clinicopathological data for baseline parameters such as age, body mass index (BMI), initial prostate-specific antigen (PSA), prostate volume on ultrasound (PV), PSA density (PSAD), D’Amico risk classification, comorbidities such as hypertension and diabetes mellitus, intra-operative parameters such as console time, blood loss, and nerve-sparing, and post-operative data such as pathological T stage, International Society of Urological Pathology (ISUP) grades, and continence status were obtained from our clinical records, prospectively collected in a customized database, and retrospectively analyzed. In all patients, we evaluated the core lower urinary tract symptom score (CLSS), a questionnaire validated for
the assessment of LUTS [10], before and after RARP. The CLSS scores obtained 3 to 6 months after RARP were extracted for this study. The clinical and pathological stages of prostate cancer were determined using the American Joint Committee on Cancer TNM staging system (8th edition). Routine follow-ups were conducted at 2 weeks, 1, 3, 6, 12 months post-discharge, and on a cycle of 6 to 12 months thereafter. All patients provided a written informed consent. This study was in accordance with the declaration of Helsinki and was approved by the institutional review board of the Tokyo University Hospital (approval no. 3124).

**Statistical analyses**

Wilcoxon rank-sum tests were used to compare continuous values between two groups. Categorical values were analyzed by Pearson’s chi-square test ($\chi^2$) and Fisher’s exact test. Waterfall plots were generated for the changes in each UFM parameter. Univariate and multivariate analyses using logistic regression models were performed to evaluate which clinical parameters were associated with peri-operative changes in UFM results. Cutoff values used for logistic regression were determined from parameter interquartiles and rounded to the nearest clinically significant value. The cohort was then stratified by the risk factors identified by multivariate analysis, and arranged in box-plots. Cutoffs for box-plots were determined by the Youden index obtained from the receiver operating characteristic (ROC) curve and rounded to the nearest clinically significant value. The association between peri-operative changes in UFM parameters and CLSS questionnaire results were analyzed by Wilcoxon nonparametric test. Kaplan-Meier cumulative event curves were drawn for post-operative continence recovery, and the log-rank test was performed to compare recovery between groups. The cutoff value for these groups were determined from parameter interquartiles and rounded to the nearest clinically significant value, similarly to the logistic regression analysis. A P-value of $< 0.05$ was considered statistically significant. All statistical analyses were performed using JMP Pro® software, version 14.2 (SAS, Cary, NC, USA).
Results

Demographics of the subjects and results of UFM pre- and post- RARP are shown in Table 1A. Comparison of pre- and post-RARP UFM parameters showed a significant increase in maximum flow rate (MFR), and significant decreases in voided volume (VV) and post-void residual urine (PVR). Median MFR increased from 14.4 to 17.1 mL/s, median VV decreased from 219 to 144 mL, and median PVR decreased from 37 to 26 mL (P values < 0.001 for all)

Table 1. Patient demographics.

| Parameters (N = 428) | Baseline and Pre-RARP | Post-RARP | P value |
|----------------------|-----------------------|-----------|---------|
| Age (years)          | 68(63–71)             |           |         |
| Pre-operative PSA (ng/mL) | 7.5(5.6–10.9)      |           |         |
| Prostate volume (mL) | 27(21–37)             |           |         |
| PSA density (ng/mL²) | 0.28(0.19–0.40)       |           |         |
| BMI (kg/m²)          | 23.7(22.0–25.3)       |           |         |
| D’Amico risk classification |                  |           |         |
| Low                  | 64(15.0%)             |           |         |
| Intermediate-high    | 364(85.0%)            |           |         |
| Pre-operative α1 blocker |                 |           |         |
| No                   | 394(92.1%)            |           |         |
| Yes                  | 34(7.9%)              |           |         |
| HT                   |                       |           |         |
| absent               | 248(57.9%)            |           |         |
| present              | 180(42.1%)            |           |         |
| DM                   |                       |           |         |
| absent               | 361(84.3%)            |           |         |
| present              | 67(15.7%)             |           |         |
| Console time (min)   | 169(130–204)          |           |         |
| Blood loss (mL)      | 250(100–500)          |           |         |
| Nerve sparing        |                       |           |         |
| none                 | 301(70.3%)            |           |         |
| unilateral           | 122(28.5%)            |           |         |
| bilateral            | 5(1.2%)               |           |         |
| pT stage             |                       |           |         |
| T2                   | 297(69.4%)            |           |         |
| T3                   | 131(30.6%)            |           |         |
| UFM parameters (mL)  |                       |           |         |
| MFR                  | 14.4(9.9–19.7)        | 17.1(11.8–24.4) | < 0.001*|
| VV                   | 219(143–328)          | 144(89–228) | < 0.001*|
| PVR                  | 37(21–67)             | 26(15–43) | < 0.001*|
| CLSS                 | total                 | 6(3–8)    | 8 (5–10) | < 0.001* |
|                      | QOL index             | 3(2–4)    | 3(2–5)   | < 0.001* |

*: statistically significant
Median value(IQR) or number of cases(%)

Abbreviations RARP: robot-assisted radical prostatectomy, PSA: prostate-specific antigen, BMI: body mass index, HT: hypertension, DM: diabetes mellitus, pT stage: pathological T stage, UFM: uroflowmetry, MFR: maximum flow rate, VV: voided volume, PVR: post-void residual urine, CLSS: core lower urinary tract symptom score, QOL index: quality of life index

https://doi.org/10.1371/journal.pone.0275069.t001
three parameters). These tendencies were confirmed in waterfall plots of the change in each UFM parameter (Fig 2). VV decreased by over 150 mL in 106 patients (24.8%). PVR decreased by over 50 mL in 82 patients (19.2%). MFR increased by over 10 mL/s in 106 patients (24.8%). Using these outcomes, we further analyzed the baseline demographics for each group as stratified by the outcomes of these perioperative changes in each UFM parameter (S1–S3 Tables).

CLSS total score and QOL index were significantly increased post-RARP, representing a worsening of LUTS (Table 1, P value < 0.01). As for the individual parameters, CLSS results showed a significant worsening of daytime and nighttime frequency, urgency and stress incontinence, straining, and urethral pain. Conversely, there was a significant improvement in the slow stream parameter (Table 2, P value < 0.01).

Predictors of these changes in UFM parameters were analyzed by logistic regression as shown in Table 3. For a decrease in VV of greater than 150 mL, none of the examined parameters exhibited a significant relation. For a decrease in PVR of greater than 50 mL, univariate analysis identified PV, console time, and blood loss as positive predictors. In multivariate analysis, PV remained the sole significant predictor of PVR decrease. For an increase in MFR of greater than 10 mL/s, univariate analysis identified age, PV, and BMI as significant predictors. In multivariate analysis, age and PV remained significant predictors of MFR increase. When divided into groups using these predictors, a statistically significant difference in PVR or MFR between the groups was seen in each (Fig 3).

The perioperative change of the individual parameters of CLSS were analyzed for their association with UFM parameters (Table 4). A decrease in VV of over 150 mL led to increased urge and stress incontinence. A decrease in PVR of over 50 mL led to decreased daytime...
Table 2. Comparison of pre- and post-operative results of CLSS questionnaire.

|                      | pre-RARP | post-RARP | P value |
|----------------------|----------|-----------|---------|
| Daytime frequency    | 0.96     | 1.16      | < 0.01  |
| Nocturia             | 1.19     | 1.55      | < 0.01  |
| Urgency              | 0.74     | 0.81      | 0.201   |
| Urgency incontinence | 0.17     | 0.70      | < 0.01  |
| Stress incontinence  | 0.04     | 1.29      | < 0.01  |
| Slow stream          | 1.19     | 0.86      | < 0.01  |
| Straining            | 0.74     | 0.87      | < 0.01  |
| Incomplete emptying  | 0.10     | 0.12      | 0.332   |
| Bladder pain         | 0.10     | 0.17      | 0.018   |
| Total CLSS Score     | 5.79     | 8.10      | < 0.01  |

*: statistically significant

Values represent mean CLSS parameter score (larger numbers = stronger symptoms)

https://doi.org/10.1371/journal.pone.0275069.t002

Table 3. Analysis of risk factors for perioperative change in uroflowmetry parameters.

|                      | ΔVV (< -150mL vs. ≥ 150mL) | ΔPVR (< -50mL vs. ≥ 50mL) | ΔMFR (> +10mL/s vs. ≤ +10mL/s) |
|----------------------|---------------------------|---------------------------|-------------------------------|
|                      | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate |
|                      | OR  | 95%CI | P value | OR  | 95%CI | P value | OR  | 95%CI | P value | OR  | 95%CI | P value |
| Age                  | 0.973 | 0.939–1.009 | 0.133 | 0.976 | 0.942–1.024 | 0.189 | 1.027 | 0.986–1.072 | 0.199 | 0.962 | 0.929–0.997 | <0.01* | 0.954 | 0.919–0.990 | <0.01* |
| Pre-op PSA           | 0.979 | 0.938–1.012 | 0.239 | 1.023 | 0.992–1.053 | 0.140 | 1.017 | 0.986–1.048 | 0.295 | 0.991 | 0.955–1.022 | 0.603 | 1.029 | 1.014–1.044 | <0.01* |
| PV                   | 0.988 | 0.971–1.003 | 0.121 | 0.989 | 0.973–1.005 | 0.171 | 1.033 | 1.018–1.048 | <0.01* | 1.029 | 1.014–1.044 | <0.01* | 1.017 | 1.004–1.031 | 0.014* |
| PSA density          | 0.857 | 0.341–1.859 | 0.711 | 0.727 | 0.240–1.749 | 0.507 | 0.917 | 0.240–1.749 | 0.507 | 0.917 | 0.240–1.749 | 0.507 | 0.917 | 0.240–1.749 | 0.507 |
| BMI                  | 0.976 | 0.900–1.054 | 0.547 | 1.056 | 0.972–1.145 | 0.196 | 1.082 | 1.003–1.169 | 0.040* | 1.082 | 1.003–1.169 | 0.040* | 1.082 | 1.003–1.169 | 0.040* |
| Pre-op α1 blocker    | 1.102 | 0.473–2.363 | 0.812 | 1.863 | 0.819–3.967 | 0.132 | 1.628 | 0.710–3.735 | 0.263 | 1.102 | 0.473–2.363 | 0.812 | 1.102 | 0.473–2.363 | 0.812 |
| HT                   | 1.253 | 0.804–1.949 | 0.317 | 1.401 | 0.863–2.274 | 0.172 | 1.021 | 0.653–1.591 | 0.924 | 1.021 | 0.653–1.591 | 0.924 | 1.021 | 0.653–1.591 | 0.924 |
| DM                   | 0.856 | 0.446–1.560 | 0.620 | 1.266 | 0.654–2.336 | 0.472 | 1.751 | 0.987–3.044 | 0.055 | 1.658 | 0.910–2.962 | 0.097 | 1.658 | 0.910–2.962 | 0.097 |
| Console time         | 1.001 | 0.995–1.004 | 0.763 | 1.005 | 1.001–1.010 | 0.002* | 1.002 | 0.997–1.008 | 0.433 | 0.999 | 0.995–1.003 | 0.627 | 0.999 | 0.995–1.003 | 0.627 |
| Blood loss           | 1.000 | 0.999–1.001 | 0.489 | 1.001 | 1.000–1.001 | 0.002* | 1.001 | 0.999–1.001 | 0.220 | 0.999 | 0.999–1.001 | 0.827 | 0.999 | 0.999–1.001 | 0.827 |
| Nerve sparing        | 0.916 | 0.558–1.476 | 0.721 | 0.779 | 0.451–1.346 | 0.365 | 1.305 | 0.811–2.079 | 0.269 | 1.305 | 0.811–2.079 | 0.269 | 1.305 | 0.811–2.079 | 0.269 |

*: statistically significant

Abbreviations: pre-op PSA: preoperative prostate specific antigen, PV: preoperative prostate volume BMI: body mass index, HT: hypertension DM: diabetes mellitus, ΔMFR: perioperative change in maximum flow rate, ΔVV: perioperative change in voided volume ΔPVR: perioperative change in post-void residual urine, OR: odds ratio, CI: confidence interval

https://doi.org/10.1371/journal.pone.0275069.t003
frequency, slow stream, and bladder pain. An increase in MFR of over 10 mL/s led to decreased slow stream and straining. All three UFM parameters led to a significant change in total CLSS score. Continence recovery curves were plotted, for recovery to either pad-free status, or one pad per day or less (Fig 4). When stratified by a decrease in VV of over/under 150 mL, a significant difference was seen in both curves, with a greater decrease in VV showing association with a delay in continence recovery.

**Discussion**

Radical prostatectomy drastically alters the anatomy and function of the bladder and urethra, and in turn leads to a variety of urological complications including urinary incontinence, voiding dysfunction, and storage dysfunction [4]. Although multiple reports state that the introduction of RARP has led to a general improvement of post-operative symptoms, post-operative LUTS remains an issue of importance [11, 12]. We ourselves have conducted several

**Table 4. Perioperative changes in CLSS questionnaire results stratified by uroflowmetry parameter changes.**

| Parameter                  | ΔVV < -150mL | ΔVV ≥ -150mL | P value | ΔPVR < -50mL | ΔPVR ≥ -50mL | P value | ΔMFR ≥ +10mL/s | ΔMFR ≤ +10mL/s | P value |
|----------------------------|--------------|--------------|---------|--------------|--------------|---------|----------------|----------------|---------|
| Daytime frequency          | 0.267        | 0.087        | 0.124   | -0.086       | 0.182        | 0.031*  | 0.094          | 0.143          | 0.733   |
| Nocturia                   | 0.295        | 0.264        | 0.516   | 0.148        | 0.301        | 0.268   | 0.321          | 0.255          | 0.561   |
| Urgency                    | 0.057        | 0.012        | 0.755   | 0.111        | 0.555        | 0.121   | 0.075          | 0.006          | 0.567   |
| Urgency incontinence       | 0.743        | 0.413        | 0.002*  | 0.420        | 0.512        | 0.564   | 0.396          | 0.526          | 0.153   |
| Stress incontinence        | 1.390        | 1.106        | 0.014*  | 1.086        | 1.197        | 0.288   | 1.236          | 1.155          | 0.486   |
| Slow stream                | -0.362       | -0.385       | 0.735   | -0.111       | -0.111       | 0.507*  | -0.877         | -0.215         | <0.001* |
| Straining                  | 0.229        | 0.252        | 0.985   | 0.286        | 0.286        | 0.187   | 0.000          | 0.327          | 0.005*  |
| Incomplete emptying        | 0.019        | -0.137       | 0.221   | -0.247       | -0.247       | 0.156   | -0.217         | -0.059         | 0.174   |
| Bladder pain               | -0.067       | 0.047        | 0.066   | -0.086       | 0.043        | 0.037*  | 0.028          | 0.016          | 0.521   |
| Urethral pain              | 0.067        | 0.056        | 0.904   | 0.111        | 0.046        | 0.242   | 0.047          | 0.062          | 0.325   |
| Total CLSS                 | 2.613        | 1.683        | 0.015*  | 0.561        | 2.234        | 0.009*  | 1.000          | 2.214          | 0.003*  |

*: statistically significant

Values represent mean (post-RARP score–pre-RARP score)
Positive value = increased symptoms, negative value = decreased symptoms
Abbreviations CLSS: Core Lower urinary tract Symptom Score, ΔVV = perioperative change in voided volume
ΔPVR: perioperative change in post-void residual urine, ΔMFR: perioperative change in maximum flow rate

https://doi.org/10.1371/journal.pone.0275069.t004
studies to evaluate pre- and post-operative LUTS, especially concerning post-prostatectomy incontinence (PPI) [13, 14]. We have reported on the longitudinal change of CLSS and other questionnaires post-RARP and found a short-term worsening of symptoms such as nocturia, urgency urinary incontinence, and stress urinary incontinence [15]. Furthermore, studies utilizing urodynamics have provided objective data giving us insight on the complex nature of the effect of prostatectomy. Factors such as direct surgical injury, bladder/sphincter denervation, or anastomotic stricture lead to varying degrees of sphincter deficiency/instability, detrusor overactivity/underactivity/instability, impaired bladder compliance, and bladder outlet obstruction (BOO), which in turn lead to the actual symptoms such as PPI [3–7, 16–21]. The urodynamic findings attributed to these changes, such as decreased maximum urethral closing pressure, decreased functional profile length, and decreased maximum detrusor pressure at MFR have all been linked to the prevalence of PPI or a delay in its recovery [3–7, 16–21]. However, urodynamic studies remain an invasive and time-consuming method, and further exploration on less invasive testing such as UFM is warranted.

Our results showed a significant increase of MFR and decrease of VV and PVR. This is in line with past reports on post-prostatectomy UFM results [22–25]. The changes in MFR and PVR particularly seem to reflect the alleviation of BOO induced by prostate resection. This is reinforced by reports in which urodynamic studies revealed a decline of the BOO index after surgery [26]. The extent to which changes in uroflowmetry affect urinary bother may be up for debate, but our cohort exhibited an association with the changes in MFR and PVR to clinical symptoms. The sole symptom of CLSS that showed improvement post-RARP was slow stream, and this study showed that both MFR and PVR were associated with the improvement of the slow stream component. It stands to reason that PV was found to be an independent predictor for both MFR increase and PVR decline, as a larger prostate would usually lead to more severe BOO, and its resection would lead to a larger improvement in voiding parameters. The cutoff value of PV was approximately 30 mL and may be used to inform patients on post-operative improvement of slow stream. Interestingly, age was also found to be a negative predictor of an improvement in MFR of over 10 mL/s. Some studies have reported on a decrease in detrusor

![Fig 4. Post-RARP urinary continence recovery stratified by voided volume change.](https://doi.org/10.1371/journal.pone.0275069.g004)
contractility with age, which may be a reason for MFR showing less improvement after RARP in older men [27].

The decrease of VV, on the other hand, was associated with both CLSS incontinence components, and also a delay in recovery from incontinence. It is natural to postulate that VV decreases after RARP, since the reduction of bladder capacity to a varying degree is inevitable when bladder neck is dissected in such a procedure. Were this to be the case, it is expected that PV would be a predictor of the decrease of VV, in that a larger prostate would likely lead to a larger resection of the bladder neck. Interestingly, we could not identify any pre-operative factors including PV that contributed to this decrease in VV from our cohort. No previous studies have conducted multivariate analysis to identify predictors of the changes in UFM parameters, and just one report found a relation between BMI and decrease in VV [28]. In past reports, post-RARP LUTS have been attributed to such factors as sphincteric dysfunction/instability, detrusor overactivity/underactivity, and impaired compliance [3–7, 13, 16–21]. Post-operative detrusor function varies greatly depending on the case and may be either over- or under-active, the latter possibly leading to an increase in VV rather than a decrease. However, most studies seem to agree that the effects of sphincteric dysfunction/instability outweigh bladder dysfunction in the majority of cases. Therefore, it stands to reason that sphincteric dysfunction/instability would lead to an impairment of bladder storage function, and a consequent decrease in VV, even in the presence of detrusor underactivity. As noted before, PPI has also been attributed to sphincteric dysfunction/instability, and this is likely the reason why an association between VV decrease and PPI prevalence was observed in our cohort. Taken together with the improvement of BOO, it is of note that the short-term CLSS and QOL indices were both worsened from pre-surgery, which indicate that the negative effect of PPI seems to have affected patients more strongly than the positive effect of the amelioration of BOO. This is easily understandable in that PPI constitutes a large percentage of complaints in post-RARP patients, as previously reported in many reports including our own [15]. Previous reports of LUTS improving after RARP presumably represent a reversal of this relationship, with the recovery of PPI leading to amelioration of BOO becoming more prominent [11].

Several recent studies have investigated intra-operative procedures affecting post-operative morbidity, perhaps due to the flexibility of surgical procedures afforded by the introduction of RARP. Techniques such as nerve sparing, bladder neck preservation, puboprostatic ligament preservation, rhabdosphincter reconstruction, bladder neck plication, and retropubic suspension have been reported to lead to improvement in PPI [29–34]. Haga et al. found that nerve-sparing led to an increased maximum VV and improvement of post-operative LUTS [30]. Although nerve sparing did not directly correlate with the amount of VV decrease in our cohort, it may be beneficial to examine further the effect of surgical techniques such as bladder neck preservation or bladder neck plication on VV. The preservation of a funneled bladder neck attained by these two techniques is said to lead to less stretch on the bladder neck and consequently to preservation of bladder function [29, 31, 33].

Some limitations of the present study should be mentioned. First of all, the retrospective nature of the study design at a single institution may have biased the results. Especially considering the aforementioned complexity of post-prostatectomy changes, a different or larger cohort may have led to different results or cutoff values, similarly to how previous urodynamics studies have led to differing predictors of PPI. Further accumulation of evidence is crucial in confirming our results. Secondly, UFM has traditionally been considered to be reliable when the VV is above 150mL. In two Japanese studies of post-RARP UFM conducted by a single group, median VV was approximately 250mL preoperatively and 150–170mL postoperatively, similar to our own result [22, 35]. Based on these reports we decided not to exclude patients with VV under 150mL, but decided to use perioperative change in UFM parameters,
thereby ameliorating this possible bias caused by ethnicity. We also considered the use of VV beneficial to our study in that it reflected natural micturition, because the endpoints of CLSS and incontinence are both reflective of natural micturition as opposed to a controlled storage until maximum urge as in urodynamics. Perhaps due to this difference, there have been previous reports that UFM results with VV below 150mL also correlated well with storage symptoms such as number of voids, nocturnal voids, and maximum VV [36].

**Conclusion**

We examined the results of routine UFM conducted before and after prostatectomy, and found a significant increase in MFR and decrease in VV and PVR. PV was an independent predictor of the changes in MFR and PVR. These changes significantly affected improvement of voiding symptoms such as slow stream and straining, and were considered to be representative of the amelioration of BOO upon prostatectomy. The decrease in VV was associated with a worsening of stress/urge incontinence symptoms, and also a delay in incontinence recovery.

**Author contributions**

YY designed the study and supervised the process of completing the study. YT and YY performed statistical analysis and drafted the manuscript. KT, NK, YH, JM, and YY contributed to data acquisition. ST, YA, YS, TK, DY, and TF assisted in data interpretation and critical revision of the manuscript. HK assisted in data interpretation, critical revision of the manuscript, and administrative supervision. All authors read and approved the final manuscript.

**Supporting information**

S1 Data.
(XLSX)

S1 File.
(DOCX)

S1 Table. Patient demographics stratified by perioperative change in voided volume ($\Delta$VV).
(DOCX)

S2 Table. Patient demographics stratified by perioperative change in post-void residual urine ($\Delta$PVR).
(DOCX)

S3 Table. Patient demographics stratified by perioperative change in maximum flow rate ($\Delta$MFR).
(DOCX)

**Author Contributions**

- **Conceptualization:** Yuta Yamada.
- **Data curation:** Yuta Takeshima, Yuta Yamada, Kotaro Takemura, Tetsuya Fujimura.
- **Formal analysis:** Yuta Takeshima, Yuta Yamada, Kotaro Takemura.
- **Investigation:** Yuta Yamada, Naoki Kimura, Yuji Hakozaki, Jimpei Miyakawa, Yusuke Sato, Taketo Kawai, Daisuke Yamada, Tetsuya Fujimura.
Methodology: Yuta Takeshima, Yuta Yamada, Kotaro Takemura, Yoshiyuki Akiyama.

Software: Yuta Takeshima.

Supervision: Yuta Yamada, Tetsuya Fujimura, Haruki Kume.

Validation: Yuta Takeshima, Yuta Yamada, Kotaro Takemura, Satoru Taguchi, Yoshiyuki Akiyama, Daisuke Yamada.

Visualization: Yuta Takeshima, Kotaro Takemura.

Writing – original draft: Yuta Takeshima, Yuta Yamada, Kotaro Takemura.

Writing – review & editing: Yuta Takeshima, Yuta Yamada, Naoki Kimura, Yuji Hakozaki, Jimpei Miyakawa, Satoru Taguchi, Yoshiyuki Akiyama, Yusuke Sato, Takeo Kawai, Daisuke Yamada.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71: 7–33. https://doi.org/10.3322/caac.21654 PMID: 33433946

2. Basiri A, de la Rosette JJ, Tabatabaei S, Woo HH, Laguna MP, Shemshaki H. Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner? World J Urol. 2018; 36: 609–621. https://doi.org/10.1007/s00345-018-2174-1 PMID: 29382896

3. Mucciardi G, Gali A, Inerrera A, Di Benedetto A, Maccione L, Mucciardi M, et al. Longitudinal observational cohort study about detrusor underactivity as a risk factor for bladder neck contracture after radical prostatectomy. Int Urol Nephrol. 2013; 45: 721–726.

4. Porena M, Meartin E, Meartin L, Vianello A, Giannantoni A. Voiding dysfunction after radical retropubic prostatectomy: more than external sphincter deficiency. Eur Urol 2007; 52: 38–45.

5. Kadono Y, Ueno S, Iwamoto D, Takezawa Y, Nohara T, Izumi K, et al. Chronological urodynamic evaluation of changing bladder and urethral functions after robot-assisted radical prostatectomy. Urology. 2015; 85: 1441–1447. https://doi.org/10.1016/j.urology.2015.02.029 PMID: 25863842

6. Majima T, Matsukawa Y, Funahashi Y, Kato M, Sassa N, Gotoh M. Urodynamic evaluation before and after to RARP to identify pre and intraoperative factors affecting postoperative continence. Neurourol Urodyn. 2021; 40: 1147–1153. https://doi.org/10.1002/nau.24650 PMID: 33849995

7. Song C, Lee J, Hong JH, Choo MS, Kim CS, Ahn H. Urodynamic interpretation of changing bladder function and voiding pattern after radical prostatectomy: a long-term follow-up. BJU Int. 2010; 106: 681–686. https://doi.org/10.1111/j.1464-410X.2009.09189.x PMID: 20128778

8. Bosch JL, Cardozo L, Hashim H, Hilton P, Oelke M, Robinson D. Constructing trials to show whether urodynamic studies are necessary in lower urinary tract dysfunction. Neurourol Urodyn. 2011; 30: 735–740. https://doi.org/10.1002/nau.21130 PMID: 21661022

9. Takeshima Y, Yamada Y, Teshima T, Fujimura T, Kakutani K, Hakozaki Y, et al. Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy. BMC Cancer. 2021; 21: 501; https://doi.org/10.1186/s12885-021-02410-7 PMID: 33947348

10. Homma Y, Yoshida M, Yamanishi T, Gotoh M. Core lower urinary tract symptom score questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int J Urol. 2015; 18: 816–820 (2008).

11. Ahn T, Roberts MJ, Strahan A, Malone G, Paterdis J, Wood G, et al. Improved lower urinary tract symptoms after robot-assisted radical prostatectomy: implications for survivorship, treatment selection and patient counseling. BJU Int. 2019; 123: Suppl.5, 47–53.

12. Piccini V, Novara G, Rosen RC, Artibani W, Costello A, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012; 62: 405–417. https://doi.org/10.1016/j.eururo.2012.05.045 PMID: 22749852

13. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Miyakazi H, Nakagawa T, et al. Overactive bladder is a negative predictor of achieving continence after robot-assisted radical prostatectomy. Int J Urol. 2017; 34, 749–756. https://doi.org/10.1111/iju.13411 PMID: 28697538

14. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Nakagawa T, Kume H, et al. Predictors of early continence after robot-assisted radical prostatectomy. LUTS. 2018; 10: 287–291. https://doi.org/10.1111/luts.12181 PMID: 28699263
15. Fujimura T, Igawa Y, Aizawa N, Niimi A, Yamada Y, Sugihara T, et al. Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot-assisted radical prostatectomy. Neurourol Urodyn. 2019; 38: 1067–1075. https://doi.org/10.1002/nau.23952 PMID: 30995359

16. Kielb SJ, Clemens JQ. Comprehensive urodynamic evaluation of 146 men with incontinence after radical prostatectomy. Urology. 2005; 66: 392–396.

17. Winters JC, Appell RA, Rackley RR. Urodynamic findings in postprostatectomy incontinence. Neurourol Urodyn. 1998; 17: 493–498. https://doi.org/10.1002/(sici)1520-6777(1998)17:5<493::aid-nau5>3.0.co;2-8 PMID: 9776012

18. Cameron AP, Suskind AM, Neer C, Hussain H, Montgomery J, Latini JM, et al. Functional and anatomical differences between continent and incontinent men post radical prostatectomy on urodynamics and 3T MRI: A pilot study. Neurourol Urodyn. 2015; 34: 527–532. https://doi.org/10.1002/nau.22616 PMID: 24752967

19. Groutz A, Blaivas JG, Chai KN, Weiss JP, Verhaaren M. The pathophysiology of post-radi cal prostatectomy incontinence: a clinical and video urodynamic study. J Urol. 2000; 163: 1767–1770. PMID: 10799178

20. Kleinhans B, Gerharz E, Melekos M, Weingartner K, Kabile T, Riedmiller H. Changes of urodynamic findings after radical retropubic prostatectomy. Eur Urol. 1999; 35: 217–222. https://doi.org/10.1159/00019843 PMID: 10072623

21. Majoros A, Bach D, Keszthelyi A, Hamvas A, Romics I. Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective urodynamic study). Neurourol Urodyn. 2006; 25: 2–7. https://doi.org/10.1002/nau.20190 PMID: 16224797

22. Kurimura Y, Haga N, Yanagida T, Tanji R, Onagi A, Honda R et al. The preoperative pad test as a predictor of urinary incontinence and quality of life after robot-assisted radical prostatectomy: a prospective, observational, clinical study. Int Urol Nephrol. 2020; 52: 67–76. https://doi.org/10.1007/s11255-019-02301-3 PMID: 31571159

23. Masters JG, Rice ML. Improvement in urinary symptoms after radical prostatectomy: a prospective evaluation of flow rates and symptom scores. BJU Int. 2003; 91: 795–797. https://doi.org/10.1046/j.1464-410x.2003.01231.x PMID: 12780834

24. Skarecky D, Gordon A, Babaian KN, Dhaliwal H, Morales B, Ahlering TE. Analysis of improved urinary peak flow rates after robot-assisted radical prostatectomy. J Endour. 2015; 25: 1152–1158. https://doi.org/10.1088/0034-5672/40/1/26 PMID: 26076967

25. Kumar V, Toussi H, Marr C, Hough C, Javie P. The benefits of radical prostatectomy beyond cancer control in symptomatic men with prostate cancer. BJU Int. 2004; 93: 507–509. https://doi.org/10.1111/j.1464-1095.2003.0601-z PMID: 15008719

26. Mitsui T, Tanaka H, Harabayashi T, Moriya K, Maruyama S, Abe T et al. Changes in urodynamics and lower urinary tract symptoms after radical prostatectomy: implications of preoperative detrusor contractility. LUTS 2012; 4: 82–86. https://doi.org/10.1111/j.1757-5672.2011.00133.x PMID: 26676531

27. Chen SF, Lee CL, Kuo HC. Change of detrusor contractility in patients with and without bladder outlet obstruction at ten or more years of follow-up. Sci Rep. 2019; 9: 18887; https://doi.org/10.1038/s41598-019-45366-2 PMID: 31827203

28. Ahlering TE, Eichel L, Edwards R, Skarecky DW. Impact of obesity on clinical outcomes in robotic prostatectomy. Urology. 2005; 65: 740–744. https://doi.org/10.1016/j.urology.2004.10.061 PMID: 15833519

29. Choi W, Freire MP, Soukup JR, Yin L, Lipsitz SR, Carus F, et al. Nerve-sparing technique and urinary control after robot-assisted laparoscopic prostatectomy. World J Urol. 2011; 29: 21–27. https://doi.org/10.1007/s00345-010-0601-z PMID: 20959992

30. Haga N, Hata J, Matsuoka K, Koguch T, Akaihata H, Kataoka M, et al. The impact of nerve-sparing robot-assisted radical prostatectomy on lower urinary tract function: Prospective assessment of patient-reported outcomes and frequency volume charts. Neurourol Urodyn. 2018; 37: 322–330. https://doi.org/10.1002/nau.23297 PMID: 28452451

31. Freire MP, Weinberg AC, Lei Y, Soukup JR, Lipsitz SR, Prasad SM, et al. Anatomic bladder neck preservation during robotic-assisted laparoscopic radical prostatectomy: description of technique and outcomes. Eur Urol. 2009; 56: 972–980. https://doi.org/10.1016/j.euro.2009.09.017 PMID: 19781948

32. Stolzenburg JU, Liatsikos EN, Rabenalt R, Do M, Sakelaropoulos G, Horn LC, et al. Nerve-sparing endoscopic extraperitoneal radical prostatectomy--effect of puboprostatic ligament preservation on early continence and positive margins. Eur Urol. 2006; 49: 103–111. https://doi.org/10.1016/j.euro.2005.10.002 PMID: 16314031

33. Lee DJ, Cheetham P, Badani KK. Predictors of early urinary continence after robotic prostatectomy. Can J Urol. 2010; 17: 5200–5205. PMID: 20566014
34. Coelho RF, Chauhan S, Orvieto MA, Sivaraman A, Palmer KJ, Coughlin G, et al. Influence of modified posterior reconstruction of the rhabdosphincter on early recovery of continence and anastomotic leak-age rates after robot-assisted radical prostatectomy. Eur Urol. 2011; 59: 72–80. https://doi.org/10.1016/j.eururo.2010.08.025 PMID: 20801579

35. Haga N, Aikawa K, Hoshi S, Yabe M, Akaihata H, Hata J et al. The effect of vesical adaptation response to diuresis on lower urinary tract symptoms after robot-assisted laparoscopic radical prostatectomy: a pilot proof of concept study. PLoS One. 2016; 11: e0159514, https://doi.org/10.1371/journal.pone.0159514 PMID: 27447829

36. Yoo S, Lee Y, Park J, Cho SY, Cho MC, Jeong H, et al. Voided volume <150mL on initial uroflowmetry in men with storage symptoms: Is it an unreliable test result or a sign of severe storage symptoms? PLoS One. 2019; 14: e0207208.